622834-90-6Relevant articles and documents
Discovery of N -(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4- trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): An orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist
Hodgetts, Kevin J.,Ge, Ping,Yoon, Taeyoung,Lombaert, Stéphane De,Brodbeck, Robbin,Gulianello, Michael,Kieltyka, Andrzej,Horvath, Raymond F.,Kehne, John H.,Krause, James E.,Maynard, George D.,Hoffman, Diane,Lee, Younglim,Fung, Laurence,Doller, Dario
experimental part, p. 4187 - 4206 (2011/08/21)
The design, synthesis, and structure-activity relationships of a novel series of pyrazines, acting as corticotropin releasing factor-1 (CRF-1) receptor antagonists, are described. Synthetic methodologies were developed to prepare a number of substituted p
Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonists
Corbett, Jeffrey W.,Rauckhorst, Mark R.,Qian, Fang,Hoffman, Robert L.,Knauer, Christopher S.,Fitzgerald, Lawrence W.
, p. 6250 - 6256 (2008/04/03)
Low nanomolar corticotropin releasing factor type-1 (CRF1) receptor antagonists containing unique indanylamines were identified from the heteroatom-linked pyrazine chemotype. The most potent indanylpyrazine had a Ki = 11 ± 1 nM. The
SUBSTITUTED PYRAZINE DERIVATIVES
-
Page/Page column 58-59, (2010/02/07)
The present invention provides substituted pyrazine derivatives of Formula (I), that are CRF1 receptor antagonists, including human CRF1 receptors. This invention also relates to use of compounds of the invention for treating a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders, particularly anxiety-related disorders and mood disorders.
